Search

Your search keyword '"EYE care"' showing total 9 results
9 results on '"EYE care"'

1. Management of medicines in an eye hospital.

Author

Rasiah, Ushalini and Ramasamy, Dhivya

Subjects
*SPECIALTY hospitals, *MATERIALS management, *EYE care, *INVENTORIES, *HOSPITAL pharmacies, *MEDICATION therapy management, *DRUGS, *MEDICAL prescriptions
Published
2023

2. OCULAR SURFACE DISEASE AMONG PATIENTS WITH OPEN ANGLE GLAUCOMA USING TOPICAL ANTI-GLAUCOMA MEDICATIONS.

Author

Javaid, Hassaan, Zafar, Omar, Akram, Seemal, Abbas, Sana, Khan, Ikram Ullah, and Javaid, Haroon

Subjects
*OPEN-angle glaucoma, *DRUGS, *EYE care, *BIMATOPROST, *DRY eye syndromes
Abstract

Objective: To determine the frequency of ocular surface disease among patients with open angle glaucoma using topical antiglaucoma medications presenting at a tertiary care eye hospital. Study Design: Cross-sectional analytical study. Place and Duration of Study: Armed Forces Institute of Ophthalmology, Rawalpindi, from May 2019 to Jan 2020. Methodology: One hundred and eighty patients aged 18 or more, with open angle glaucoma using any of the topical antiglaucoma medications including preparations of dorzolamide, brimonidine, timolol, levobunolol, betaxolol, latanoprost, travoprost, bimatoprost or a combination of these for more than six months took part in the study. Ocular surface disease index was used to assess the presence and severity of ocular surface disease. Results: Out of 180 patients of glaucoma managed with topical anti-glaucoma medications, 83 (46.1%) did not show presence of ocular surface disease when ocular surface disease index was administered. Twenty-nine (16.1%) patients had mild symptoms, 17 (9.4%) had moderate symptoms while 51 (28.3%) patients reported severe symptoms of ocular surface disease. Advancing age and longer duration of treatment with topical anti-glaucoma medications had statistically significant association with the presence of ocular surface disease (p-value <0.05). Conclusion: Presence of ocular surface disease was a common finding among patients using topical agents for the management of glaucoma. Advancing age and prolonged use of anti-glaucoma medication emerged as risk factors statistically related to the presence of ocular surface disease. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

3. Researchers' Work from Allergan Plc Focuses on Pharmaceuticals (Evaluation of the Impact of Meibomian Gland Dysfunction Using a Novel Patient-reported Outcome Instrument).

Subjects
MEIBOMIAN glands, RESEARCH personnel, DRUGS, OCULAR pharmacology, EYE care
Abstract

A recent study conducted by researchers at Allergan Plc in Irvine, California aimed to assess the impact of meibomian gland dysfunction (MGD) on patients' quality of life. The study categorized eligible individuals into non-MGD, mild/moderate MGD, or severe MGD cohorts based on ocular symptoms, Schirmer score, and meibum quality. The results showed that as MGD severity increased, patients experienced greater difficulty with vision-related activities, such as reading and performing leisure activities. The study concluded that the MGD Impact Questionnaire (MGD IQ) can be a valuable tool in characterizing disease severity and incorporating the patient's perspective in clinical research. [Extracted from the article]

Published
2024

4. New Glaucoma Research from Smt NHL Municipal Medical College Outlined (A Case Control Study on Risk Factors and Drug Prescription Patterns in Glaucoma at a tertiary eye care center in a city of Western India).

Subjects
DRUG prescribing, DRUGS, EYE care, MEDICAL schools, GLAUCOMA
Abstract

Keywords: Clinical Research; Clinical Trials and Studies; Drug Prescriptions; Drugs and Therapies; Eye Diseases and Conditions; Glaucoma; Health and Medicine; Risk and Prevention EN Clinical Research Clinical Trials and Studies Drug Prescriptions Drugs and Therapies Eye Diseases and Conditions Glaucoma Health and Medicine Risk and Prevention 359 359 1 05/22/23 20230523 NES 230523 2023 MAY 22 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Fresh data on glaucoma are presented in a new report. This was an observational, case-control study including 165 adult Glaucoma patients on treatment as cases and 165 age and sex-matched healthy individuals as controls, all of which were randomly selected from the patients visiting a tertiary eye care center. The news correspondents obtained a quote from the research from Smt NHL Municipal Medical College: "To identify the various ocular and non ocular risk factors of glaucoma and to identify the drug prescription pattern among glaucoma patients. [Extracted from the article]

Published
2023

5. Medicines for eye health.

Author

Kyari, Fatima and Wolvaardt, Elmien

Subjects
*TEAMS in the workplace, *HEALTH services accessibility, *EYE care, *OPHTHALMIC drugs, *DRUGS, *QUALITY assurance, *INTERPROFESSIONAL relations, *COMMUNICATION, *PATIENT compliance, *EYE diseases
Published
2023

7. mHealth for eye care: what is possible?

Author

Morjaria, Priya and Massie, Jessica

Subjects
*CELL phones, *EVALUATION of medical care, *HEALTH services accessibility, *EYE care, *HUMAN services programs, *QUALITY assurance, *DRUGS, *PATIENT compliance, *PATIENT education, *TELEMEDICINE
Published
2022

8. Netarsudil provides IOP lowering in goniotomy treated eyes: Unique MOA may deliver synergistic effect when prescribed post-surgically.

Author

Haochen (Emily) Xu and An, Jella

Subjects
*INTRAOCULAR pressure, *AQUEOUS humor, *EYE care, *MEASUREMENT of angles (Geometry), *OPHTHALMIC drugs, *DRUGS, *DRUG side effects, *PATIENT compliance, *INSURANCE, *PHARMACODYNAMICS, GLAUCOMA surgery
Abstract

The article discusses a study which compared the intraocular pressure (IOP) lowering effects of netarsudil ophthalmic solution 0.02% on eyes with previous Kahook Dual Blade goniotomy versus goniotomy-naïve eyes. Topics covered include the KDB goniotomy, a common micro-invasive glaucoma surgery, the mechanisms in which netarsudil lower IOP and the results and recommendations of the study.

Published
2021

9. Manage dry eye disease with prevention, protection, prescriptions: Focusing on patients' nutrition and hygiene can boost visual performance.

Author

Charters, Lynda

Subjects
*DRY eye syndromes, *EYE protection, *EYE care, *HYGIENE, *OPHTHALMIC drugs, *NUTRITION education, *DRUGS, *VISION
Abstract

The article discusses how dry eye disease can be manage through nutrition, hygiene, visual performance and neural stimulation. According to Doctor Laura M. Periman of Periman Eye Institute, preventive mechanisms are effective in treating dry eye disease. Also cited are treatments like lifitegrast (Xiidra) from Novartis and cyclosporine 0.05%.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results